SCHEMBL4746015

SCHEMBL4746015

c1cnc2c(c1)-c1cccc3c1c-2cc1c2ccccc2c(-c2cnc4ccccc4c2)cc31

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.45
PDGFRA P16234 3/20 0.45
CYP2A6 P11509 1/20 0.44
BMPR1B O00238 1/20 0.41
PIK3C2G O75747 1/20 0.41
CDKL5 O76039 1/20 0.41
PIM1 P11309 1/20 0.41
TYK2 P29597 1/20 0.41
CLK2 P49760 1/20 0.41
DYRK1A Q13627 1/20 0.41
STK32B Q9NY57 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
IRAK3 Q9Y616 1/20 0.41
HSP90AA1 P07900 5/20 0.41
BIRC5 O15392 1/20 0.40
ATR Q13535 2/20 0.39
ATRIP Q8WXE1 2/20 0.39
TOP2A P11388 2/20 0.39
TOP2B Q02880 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746017 0.89 POLB (0.49) TYK2DYRK1AATRATRIPNPC1
SCHEMBL13320340 0.87 PDGFRB (0.51) PDGFRBPDGFRACYP2A6HSP90AA1BIRC5
SCHEMBL4746252 0.85 ALDH1A1 (0.41) TOP2ANPC1POLBRAB9AALDH1A1
SCHEMBL4745816 0.84 HTR2B (0.40) PIM1TOP2ANPC1RAB9AALDH1A1
SCHEMBL4746386 0.83 ALDH1A1 (0.38) TOP2AALDH1A1HPGDTSHRMAPK1
SCHEMBL4746287 0.83 PTPRC (0.39) TOP2AALDH1A1HPGDTSHRMAPK1
SCHEMBL4746335 0.83 ALDH1A1 (0.39) TOP2APIK3CDALDH1A1HPGDTSHR
SCHEMBL13320390 0.82 ALDH1A1 (0.45) TOP2AALDH1A1HPGDTSHRMAPK1
SCHEMBL4746241 0.82 ALDH1A1 (0.42) TOP2AALDH1A1HPGDTSHRMAPK1
SCHEMBL4746384 0.82 ALDH1A1 (0.37) TOP2APIK3CDPIK3CBPIK3CGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 PDGFRB 2429/4885PDGFRA 1770/4885CYP2A6 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.